» Articles » PMID: 19476049

Allergic Conjunctivitis and H1 Antihistamines

Overview
Date 2009 May 30
PMID 19476049
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Allergic conjunctivitis is the most common form of ophthalmological allergy. Eye symptoms are one of the main and most frequent reasons for consultation among patients with allergic rhinoconjunctivitis, which in turn is the most common reason for visiting the allergologist, according to the Alergológica 2005 study. Itching is the key symptom of allergic conjunctivitis, and its relief is the principal objective of the broad range of treatment options available. Topical antihistamines with multiple actions (mast cell stabilization, and antiinflammatory and antihistaminic actions) are probably the best treatment option, thanks to their rapid action, safety and convenience of use. However, oral antihistamines (preferentially second generation drugs) can also play an important role, since they are of established efficacy and offer adequate treatment of the nasal symptoms that tend to accompany the ocular manifestations of allergic rhinoconjunctivitis. Models of allergic conjunctivitis are useful for investigational purposes and for advancing our knowledge of allergic reactions. Advances in the study of the physiopathology of ocular allergy allow us to introduce new therapeutic options for the management of such allergic reactions, thanks to the findings derived from models of this kind. The present review provides an update to the published data on allergic conjunctivitis and the current role of both topical and ocular antihistamines in treating the disorder.

Citing Articles

The new bilastine eye drop formulation protects against conjunctival dehydration and promotes corneal wound healing in a comparative in vitro study.

Arana E, Gonzalo A, Andollo N, Perez-Garrastachu M, Otero-Espinar F, Diaz-Tome V Sci Rep. 2025; 15(1):7987.

PMID: 40055363 PMC: 11889099. DOI: 10.1038/s41598-025-91743-0.


Formulation and Pathohistological Study of Mizolastine-Solid Lipid Nanoparticles-Loaded Ocular Hydrogels.

El-Emam G, Girgis G, Hamed M, Soliman O, Abd El Gawad A Int J Nanomedicine. 2021; 16:7775-7799.

PMID: 34853513 PMC: 8627895. DOI: 10.2147/IJN.S335482.


Brazilian guidelines for the monitoring and treatment of pediatric allergic conjunctivitis.

Ronconi C, Issaho D, Ejzenbaum F, Hopker L, Sole D, Chong Neto H Arq Bras Oftalmol. 2021; 85(4):415-425.

PMID: 34852049 PMC: 11878402. DOI: 10.5935/0004-2749.20220053.


Maresin 1, a specialized proresolving mediator, stimulates intracellular [Ca ] and secretion in conjunctival goblet cells.

Olsen M, Lyngstadaas A, Bair J, Hodges R, Utheim T, Serhan C J Cell Physiol. 2020; 236(1):340-353.

PMID: 32510663 PMC: 7722204. DOI: 10.1002/jcp.29846.


Potential Biomarkers for Allergic Conjunctival Diseases.

Roy N, Levanon S, Asbell P Eye Contact Lens. 2020; 46 Suppl 2:S109-S121.

PMID: 32097185 PMC: 7122043. DOI: 10.1097/ICL.0000000000000688.